Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease.

C3 glomerular deposits anti-glomerular basement membrane disease complement C3 kidney biopsy kidney prognosis kidney survival

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 20 03 2023
accepted: 20 06 2023
medline: 24 7 2023
pubmed: 21 7 2023
entrez: 21 7 2023
Statut: epublish

Résumé

Activation of the complement system is involved in the pathogenesis of anti-glomerular basement membrane (anti-GBM) disease. Glomerular deposits of complement 3 (C3) are often detected on kidney biopsies. The primary objective of this study was to analyze the prognostic value of the serum C3 level and the presence of C3 glomerular deposits in patients with anti-GBM disease. We conducted a retrospective cohort study of 150 single-positive patients with anti-GBM disease diagnosed between 1997 and 2017. Patients were categorized according to the serum C3 level (forming a low C3 (C3<1.23 g/L) and a high C3 (C3≥1.23 g/L) groups) and positivity for C3 glomerular staining (forming the C3+ and C3- groups). The main outcomes were kidney survival and patient survival. Of the 150 patients included, 89 (65%) were men. The median [interquartile range (IQR)] age was 45 [26-64]. At diagnosis, kidney involvement was characterized by a median [IQR] peak serum creatinine (SCr) level of 578 [298-977] µmol/L, and 106 (71%) patients required dialysis. Patients in the low C3 group (72 patients) had more severe kidney disease at presentation, as characterized by higher prevalences of oligoanuria, peak SCr ≥500 µmol/L (69%, vs. 53% in the high C3 group; p=0.03), nephrotic syndrome (42%, vs. 24%, respectively; p=0.02) and fibrous forms on the kidney biopsy (21%, vs. 8%, respectively; p=0.04). Similarly, we observed a negative association between the presence of C3 glomerular deposits (in 52 (41%) patients) and the prevalence of cellular forms (83%, vs. 58% in the C3- group; p=0.003) and acute tubulo-interstitial lesions (60%, vs. 36% in the C3- group; p=0.007). When considering patients not on dialysis at diagnosis, the kidney survival rate at 12 months was poorer in the C3+ group (50% [25-76], vs. 91% [78-100] in the C3- group; p=0.01), with a hazard ratio [95% confidence interval] of 5.71 [1.13-28.85] (p=0.04, after adjusting for SCr). In patients with anti-GBM disease, a low serum C3 level and the presence of C3 glomerular deposits were associated with more severe disease and histological kidney involvement at diagnosis. In patients not on dialysis at diagnosis, the presence of C3 deposits was associated with worse kidney survival.

Sections du résumé

Background and objectives
Activation of the complement system is involved in the pathogenesis of anti-glomerular basement membrane (anti-GBM) disease. Glomerular deposits of complement 3 (C3) are often detected on kidney biopsies. The primary objective of this study was to analyze the prognostic value of the serum C3 level and the presence of C3 glomerular deposits in patients with anti-GBM disease.
Methods
We conducted a retrospective cohort study of 150 single-positive patients with anti-GBM disease diagnosed between 1997 and 2017. Patients were categorized according to the serum C3 level (forming a low C3 (C3<1.23 g/L) and a high C3 (C3≥1.23 g/L) groups) and positivity for C3 glomerular staining (forming the C3+ and C3- groups). The main outcomes were kidney survival and patient survival.
Results
Of the 150 patients included, 89 (65%) were men. The median [interquartile range (IQR)] age was 45 [26-64]. At diagnosis, kidney involvement was characterized by a median [IQR] peak serum creatinine (SCr) level of 578 [298-977] µmol/L, and 106 (71%) patients required dialysis. Patients in the low C3 group (72 patients) had more severe kidney disease at presentation, as characterized by higher prevalences of oligoanuria, peak SCr ≥500 µmol/L (69%, vs. 53% in the high C3 group; p=0.03), nephrotic syndrome (42%, vs. 24%, respectively; p=0.02) and fibrous forms on the kidney biopsy (21%, vs. 8%, respectively; p=0.04). Similarly, we observed a negative association between the presence of C3 glomerular deposits (in 52 (41%) patients) and the prevalence of cellular forms (83%, vs. 58% in the C3- group; p=0.003) and acute tubulo-interstitial lesions (60%, vs. 36% in the C3- group; p=0.007). When considering patients not on dialysis at diagnosis, the kidney survival rate at 12 months was poorer in the C3+ group (50% [25-76], vs. 91% [78-100] in the C3- group; p=0.01), with a hazard ratio [95% confidence interval] of 5.71 [1.13-28.85] (p=0.04, after adjusting for SCr).
Conclusion
In patients with anti-GBM disease, a low serum C3 level and the presence of C3 glomerular deposits were associated with more severe disease and histological kidney involvement at diagnosis. In patients not on dialysis at diagnosis, the presence of C3 deposits was associated with worse kidney survival.

Identifiants

pubmed: 37475859
doi: 10.3389/fimmu.2023.1190394
pmc: PMC10354545
doi:

Substances chimiques

Complement C3 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1190394

Informations de copyright

Copyright © 2023 Caillard, Vigneau, Halimi, Hazzan, Thervet, Heitz, Juillard, Audard, Rabant, Hertig, Subra, Vuiblet, Guerrot, Tamain, Essig, Lobbedez, Quemeneur, Legendre, Ganea, Peraldi, Vrtovsnik, Daroux, Makdassi, Choukroun and Titeca-Beauport.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Semin Respir Crit Care Med. 2018 Aug;39(4):494-503
pubmed: 30404116
Nat Rev Immunol. 2019 Aug;19(8):503-516
pubmed: 31048789
BMC Nephrol. 2017 Jul 11;18(1):231
pubmed: 28697742
Front Immunol. 2020 Sep 03;11:2035
pubmed: 33013861
Front Immunol. 2022 Jul 08;13:929155
pubmed: 35874697
J Autoimmun. 2016 Sep;73:24-9
pubmed: 27267459
BMC Nephrol. 2019 Aug 9;20(1):313
pubmed: 31399080
Nat Rev Nephrol. 2017 Jun;13(6):359-367
pubmed: 28316335
Kidney Int. 2016 Apr;89(4):897-908
pubmed: 26994577
Nephrol Dial Transplant. 2015 May;30(5):814-21
pubmed: 25609740
J Am Soc Nephrol. 2010 Oct;21(10):1628-36
pubmed: 20616173
Nephrol Dial Transplant. 1998 Nov;13(11):2799-803
pubmed: 9829481
Ren Fail. 2020 Nov;42(1):845-852
pubmed: 32787590
Kidney Int. 2013 Jan;83(1):129-37
pubmed: 22913983
J Am Soc Nephrol. 2001 Sep;12(9):1908-1915
pubmed: 11518784
Kidney Int. 2003 Nov;64(5):1685-94
pubmed: 14531801
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211039391
pubmed: 34595959
Nephrol Dial Transplant. 2022 Oct 28;:
pubmed: 36307926
Clin Chim Acta. 2017 Feb;465:123-130
pubmed: 28040558
Sci China Life Sci. 2016 Dec;59(12):1282-1289
pubmed: 27080546
Arthritis Res Ther. 2015 May 21;17:129
pubmed: 25994214
N Engl J Med. 2021 Feb 18;384(7):599-609
pubmed: 33596356
Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1171-F1182
pubmed: 31461345
Ann Intern Med. 2001 Jun 5;134(11):1033-42
pubmed: 11388816
Kidney Int. 2018 Dec;94(6):1177-1188
pubmed: 30385041
Semin Respir Crit Care Med. 2011 Jun;32(3):310-21
pubmed: 21674416
J Immunol. 2009 Sep 15;183(6):3980-8
pubmed: 19710463
Nephrol Dial Transplant. 2009 Apr;24(4):1247-52
pubmed: 18940884
Front Immunol. 2019 Jul 18;10:1665
pubmed: 31396214
Clin Exp Immunol. 1997 Jul;109(1):134-42
pubmed: 9218836
J Am Soc Nephrol. 1995 Oct;6(4):1178-85
pubmed: 8589284
Curr Rheumatol Rep. 2021 Feb 10;23(3):16
pubmed: 33569681
Nat Rev Immunol. 2007 Jan;7(1):9-18
pubmed: 17170757
Am J Clin Pathol. 2006 Mar;125(3):445-50
pubmed: 16613350
Kidney Int Rep. 2022 Mar 04;7(6):1165-1178
pubmed: 35685323
Am J Nephrol. 2022;53(5):397-406
pubmed: 35462364
Front Immunol. 2020 Dec 10;11:599417
pubmed: 33362783
Int J Nephrol Renovasc Dis. 2022 Apr 07;15:129-138
pubmed: 35418771
Mol Immunol. 2020 Dec;128:175-187
pubmed: 33137606
J Nephrol. 2018 Apr;31(2):257-262
pubmed: 29027625
Clin J Am Soc Nephrol. 2018 Jan 6;13(1):63-72
pubmed: 29162595
Clin Rev Allergy Immunol. 2020 Apr;58(2):229-251
pubmed: 31834594
Clin Exp Immunol. 1997 Dec;110(3):403-9
pubmed: 9409643
J Clin Immunol. 2013 Jan;33(1):172-8
pubmed: 22941511
PLoS One. 2014 Mar 21;9(3):e91250
pubmed: 24658070
J Am Soc Nephrol. 2017 Sep;28(9):2756-2767
pubmed: 28400446
J Immunol. 2006 Sep 15;177(6):4094-102
pubmed: 16951374
J Clin Pathol. 2019 Jan;72(1):31-37
pubmed: 30315136
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Clin Exp Immunol. 1995 May;100(2):262-8
pubmed: 7743665
J Am Soc Nephrol. 2023 Mar 1;34(3):505-514
pubmed: 36446430
Front Med (Lausanne). 2022 Jul 05;9:889185
pubmed: 35865174
PLoS One. 2016 Jul 08;11(7):e0158871
pubmed: 27391243

Auteurs

Pauline Caillard (P)

Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France.
Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires (MP3CV) laboratory, Centre de Recherche en Santé (CURS), Amiens, France.

Cécile Vigneau (C)

Rennes University Hospital, Inserm, Ecole des hautes études en santé publique (EHESP), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.

Jean-Michel Halimi (JM)

Department of Nephrology, Tours University Hospital and EA4245, University of Tours, Tours, France.

Marc Hazzan (M)

Nephrology Department, Lille University Hospital, University of Lille, UMR 995, Lille, France.

Eric Thervet (E)

Department of Nephrology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris and INSERM UMRS970, Boulogne-Billancourt, France.

Morgane Heitz (M)

Department of Nephrology and Dialysis, Annecy Genevois Hospital, Pringy, France.

Laurent Juillard (L)

Department of Nephrology, Edouard Herriot Hospital, Hospices Civils de Lyon, Carmen INSERM 1060 and Univ Lyon, Lyon, France.

Vincent Audard (V)

Department of Nephrology and Renal Transplantation, Reference Center-Idiopathic Nephrotic Syndrome, Henri-Mondor Hospital/Albert-Chenevier, Assistance Publique-Hôpitaux de Paris (AP-HP) Créteil, INSERMU955, Paris Est Créteil University, Créteil, France.

Marion Rabant (M)

Pathology Department, Necker University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Centre-Université de Paris, Paris, France.

Alexandre Hertig (A)

Department of Nephrology, Dialysis and Transplantation, Foch Hospital, Paris-Saclay University, Suresnes, France.

Jean-François Subra (JF)

Department of Nephrology, Dialysis and Transplantation, University Hospital, Angers and Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), INSERM, Nantes University, Angers University, Angers, France.

Vincent Vuiblet (V)

Department of Nephrology and Renal Transplantation, Reims University Hospital, Reims, France.

Dominique Guerrot (D)

Department of Nephrology, Rouen University Hospital, Rouen and INSERM, U1096 Rouen, France.

Mathilde Tamain (M)

Department of Nephrology and Dialysis, Vichy Hospital, Vichy, France.

Marie Essig (M)

Department of Nephrology, Dialysis, and Renal Transplantation, Ambroise-Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Boulogne-Billancourt, France.

Thierry Lobbedez (T)

Department of Nephrology, Caen University Hospital, Caen, France and the French Registry of Peritoneal Dialysis, Langue Française, Pontoise, France.

Thomas Quemeneur (T)

Department of Nephrology and Internal Medicine, Valenciennes General Hospital, Valenciennes, France.

Mathieu Legendre (M)

Department of Nephrology, Dialysis and Renal Transplantation, University Hospital, Dijon, France.

Alexandre Ganea (A)

Department of Nephrology, Orleans Hospital, Orleans, France.

Marie-Noëlle Peraldi (MN)

Department of Nephrology, Dialysis and Renal Transplantation, Necker University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Centre-Université de Paris, Paris, France.

François Vrtovsnik (F)

Nephrology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France. Faculty of Medicine, Paris Diderot University, Sorbonne Paris Cité, Paris, France.

Maïté Daroux (M)

Department of Nephrology, Duchenne Hospital, Boulogne-Sur-Mer, France.

Raïfah Makdassi (R)

Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France.

Gabriel Choukroun (G)

Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France.
Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires (MP3CV) laboratory, Centre de Recherche en Santé (CURS), Amiens, France.

Dimitri Titeca-Beauport (D)

Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France.
Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires (MP3CV) laboratory, Centre de Recherche en Santé (CURS), Amiens, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH